Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Karathanasis, Efstathios ^a,d   Chan, Leslie ^a   Karumbaiah, Lohitash ^a   McNeeley, Kathleen ^a   D'Orsi, Carl J ^b   Annapragada, Ananth V ^c   Sechopoulos, Ioannis ^b   Bellamkonda, Ravi V ^a  

^a Emory University   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d Case Western Reserve University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; BIOLOGICAL MARKER; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CONTROLLED STUDY; DIGITAL MAMMOGRAPHY; DISEASE MARKER; GENE OVEREXPRESSION; INTRATUMORAL DRUG ADMINISTRATION; NANOIMAGING; NANOPROBE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; CAPILLARY PERMEABILITY; ELECTRON SPIN RESONANCE; EXPERIMENTAL NEOPLASM; METABOLISM; METHODOLOGY; NANOTECHNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION; X RAY;

ANIMALIA; RATTUS;

ANIMALS; BIOLOGICAL MARKERS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; ELECTRON SPIN RESONANCE SPECTROSCOPY; MAMMARY NEOPLASMS, ANIMAL; NANOTECHNOLOGY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; X-RAYS;

EID: 67649228025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005843     Document Type: Article

References (53)

1. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
2. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974.
3. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
4. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.
5. Stetler-Stevenson WG (2001) The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 10: 383-392, x.
6. Ferrara N (2005) The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. pp 209-231.
7. Yamaji-Kegan K, Su Q, Angelini DJ, Champion HC, Johns RA (2006) Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2. Am J Physiol Lung Cell Mol Physiol 291: L1159-1168.
8. Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39: 469-478.
9. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K (2006) The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63: 601-615.
10. Fox SB, Generali DG, Harris AL (2007) Breast tumour angiogenesis. Breast Cancer Res 9: 216.
11. Relf M, LeJeune S, Scott PA, Fox S, Smith K, et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-969.
12. Fox SB, Gasparini G, Harris AL (2001) Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2: 278-289.
13. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R (2006) Adrenomedullin and tumour angiogenesis. Br J Cancer 94: 1-7.
14. Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 (Suppl 1): 37-44.
15. Gasparini G (2001) Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 37: 97-114.
16. Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16: 3121-3128.
17. Kim EA, Gershtein ES, Vysotskaya IV, Kushlinskii NE (2008) Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer. Bull Exp Biol Med 145: 245-248.
18. Raatschen HJ, Simon GH, Fu Y, Sennino B, Shames DM, et al. (2008) Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 247: 391-399.
19. Hylton N (2006) Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24: 3293-3298.
20. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97: 172-187.
21. Nunes FL, Schiabel H, Benatti RH (2002) Contrast enhancement in dense breast images using the modulation transfer function. Med Phys 29: 2925-2936.
22. Brix G, Semmler W, Port R, Schad LR, Layer G, et al. (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15: 621-628.
23. Larsson HBW, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, et al. (1990) Quantitation of blood-brain barrier defects by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 16: 117-131.
24. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Magn Reson Med 17: 357-367.
25. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7: 91-101.
26. Chen K, Cai W, Li ZB, Wang H, Chen X (2009) Quantitative PET Imaging of VEGF Receptor Expression. Mol Imaging Biol 11: 15-22.
27. Chen K, Li ZB, Wang H, Cai W, Chen X (2008) Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 35: 2235-2244.
28. Maeda H (2001) SMANCS and Polymer-Conjugated Macromolecular Drugs: Advantages in Cancer Chemotherapy. Adv Drug Deliv Rev 46: 169-185.
29. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284.
30. Karathanasis E, Chan L, Balusu SR, D'Orsi CJ, Annapragada AV, et al. (2008) Multifunctional nanocarriers for mammographic quantification of tumor dosing and prognosis of breast cancer therapy. Biomaterials 29: 4815-4822.
31. Karathanasis E, Suryanarayanan S, Balusu SR, McNeeley K, Sechopoulos I, et al. (2009) Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. Radiology 250: 398-406.
32. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, et al. (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353: 1773-1783.
33. Hubbell JH, Seltzer SM (1996) Tables of X-Ray Mass Attenuation Coefficients and Mass Energy-Absorption Coefficients. Accessed 12/05/ 2007; http://physics.nist.gov/PhysRefData/XrayMassCoef/cover.html.
34. Karathanasis E, Park J, Agarwal A, Patel V, Zhao F, et al. (2008) MRI mediated, non-invasive tracking of intratumoral distribution of nanocarriers in rat glioma. Nanotechnology 19: 315101(315109pp).
35. Brown BW, Atkinson EN, Bartoszynski R, Thompson JR, Montague ED (1984) Estimation of human tumor growth rate from distribution of tumor size at detection. J Natl Cancer Inst 72: 31-38.
36. Lasic D, Martin F (1995) Stealth Liposomes. CRC Press Inc.
37. Heffelfinger SC, Yan M, Gear RB, Schneider J, LaDow K, et al. (2004) Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation. Lab Invest 84: 989-998.
38. McNeeley KM, Annapragada A, Bellamkonda RV (2007) Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 18: 385101.
39. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, et al. (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8: 1172-1181.
40. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, et al. (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66: 6732-6740.
41. Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, et al. (2007) Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J Oncol Pharm Pract 13: 39-45.
42. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743.
43. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, et al. (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7: 243-254.
44. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, et al. (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS related Kaposi's sarcoma. J Clin Pharmacol 36: 55-63.
45. Fukumura D, Jain RK (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101: 937-949.
46. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, et al. (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95: 4607-4612.
47. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, et al. (1996) Time dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93: 14765-14770.
48. Vamesu S (2008) Angiogenesis and tumor histologic type in primary breast cancer patients: an analysis of 155 needle core biopsies. Rom J Morphol Embryol 49: 181-188.
49. Wagner KU (2004) Models of breast cancer: quo vadis, animal modeling? Breast Cancer Res 6: 31-38.
50. McDonald DM, Baluk P (2002) Significance of blood vessel leakiness in cancer. Cancer Res 62: 5381-5385.
51. Drevs J, Schneider V (2006) The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J Intern Med 260: 517-529.
52. Jain RK (2005) Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science 307: 58-62.
53. Fukumura D, Jain RK (2007) Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res.